Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer

References

• Anklesaria, P., J. Teixido, M. Laiho, J. H. Pierce, J. S. Greenberger, and J. Massague. 1990. “Cell-Cell Adhesion Mediated by Binding of Membrane-Anchored Transforming Growth Factor a to Epidermal Growth Factor Receptors Promotes Cell Proliferation.” Proceedings of the National Academy of Sciences 87 (9): 3289–3293. doi:10.1073/pnas.87.9.3289
   PubMed Web of Science ®Google Scholar
• Australian Institute of Health and Welfare. 2019. “Cancer in Australia 2019.” https://www.aihw.gov.au/reports/cancer/cancer-in-australia-2019/data.
   Google Scholar
• Baker, J. B., D. Dutta, D. Watson, T. Maddala, B. M. Munneke, S. Shak, E. K. Rowinsky, et al. 2011. “Tumour Gene Expression Predicts Response to Cetuximab in Patients with KRAS Wild-Type Metastatic Colorectal Cancer.” British Journal of Cancer 104 (3): 488–495. doi:10.1038/sj.bjc.6606054.
   PubMed Web of Science ®Google Scholar
• Begg, K., and M. Tavassoli. 2017. “Review: Biomarkers towards Personalised Therapy in Cancer.” Drug Target Review 4 (2): 26–30. https://www.drugtargetreview.com/article/23631/biomarkers-personalised-therapy-cancer/.
   Google Scholar
• Bernat-Peguera, A., P. Simón-Extremera, V. da Silva-Diz, M. López de Munain, L. Díaz-Gil, R. M. Penin, E. González-Suárez, et al. 2019. “PDGFR-Induced Autocrine SDF-1 Signaling in Cancer Cells Promotes Metastasis in Advanced Skin Carcinoma.” Oncogene 38 (25): 5021–5037. doi:10.1038/s41388-019-0773-y.
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working Group. 2001. “Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework.” Clinical Pharmacology and Therapeutics 69 (3): 89–95. doi:10.1067/mcp.2001.113989.
   PubMed Web of Science ®Google Scholar
• Blobel, C. P. 2005. “ADAMs: Key Components in Egfr Signalling and Development.” Nature Reviews Molecular Cell Biology 6 (1): 32. doi:10.1038/nrm1548.
   PubMed Web of Science ®Google Scholar
• Bou-Assaly, W., and S. Mukherji. 2010. “Cetuximab (Erbitux).” American Journal of Neuroradiology 31 (4): 626–627. doi:10.3174/ajnr.A2054.
   PubMed Web of Science ®Google Scholar
• Bray, F., J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal. 2018. “Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.” CA: A Cancer Journal for Clinicians 68 (6): 394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Brown, C. L., K. S. Meise, G. D. Plowman, R. J. Coffey, and P. J. Dempsey. 1998. “Cell Surface Ectodomain Cleavage of Human Amphiregulin Precursor is Sensitive to a Metalloprotease Inhibitor: Release of a Predominant N- Glycosylated 43-KDa Soluble Form.” Journal of Biological Chemistry 273 (27): 17258–17268. doi:10.1074/jbc.273.27.17258.
   PubMed Web of Science ®Google Scholar
• Brulé, S. Y., D. J. Jonker, C. S. Karapetis, C. J. O’Callaghan, M. J. Moore, R. Wong, N. C. Tebbutt, et al. 2015. “Location of Colon Cancer (Right-Sided versus Left-Sided) as a Prognostic Factor and a Predictor of Benefit from Cetuximab in NCIC CO.17.” European Journal of Cancer 51 (11): 1405–1414. doi:10.1016/j.ejca.2015.03.015.
   PubMed Web of Science ®Google Scholar
• Bufill, J. A. 1990. “Colorectal Cancer: Evidence for Distinct Genetic Categories Based on Proximal or Distal Tumor Location.” Annals of Internal Medicine 113 (10): 779. doi:10.7326/0003-4819-113-10-779.
   PubMed Web of Science ®Google Scholar
• Burgess, A. W. 2008. “EGFR Family: Structure Physiology Signalling and Therapeutic Target.” Growth Factors 26 (5): 263–274. doi:10.1080/08977190802312844.
   PubMed Web of Science ®Google Scholar
• Cantanhede, I. G., and J. R. M. De Oliveira. 2017. “PDGF Family Expression in Glioblastoma Multiforme: Data Compilation from Ivy Glioblastoma Atlas Project Database.” Scientific Reports 7 (1): 1–9. doi:10.1038/s41598-017-15045-w.
   PubMedGoogle Scholar
• Cao, Y. 2013. “Multifarious Functions of PDGFs and PDGFRs in Tumor Growth and Metastasis.” Trends in Molecular Medicine 19 (8): 460–473. doi:10.1016/j.molmed.2013.05.002.
   PubMed Web of Science ®Google Scholar
• Carl-McGrath, S., U. Lendeckel, M. Ebert, A. Roessner, and C. Röcken. 2005. “The Disintegrin-Metalloproteinases ADAM9, ADAM12, and ADAM15 Are Upregulated in Gastric Cancer.” International Journal of Oncology 26 (1): 17–24. doi:10.3892/ijo.26.1.17.
   PubMed Web of Science ®Google Scholar
• Carpenter, G., K. J. Lembach, M. M. Morrison, and S. Cohen. 1975. “Characterization of the Binding of 125-I-Labeled Epidermal Growth Factor to Human Fibroblasts.” The Journal of Biological Chemistry 250 (11): 4297–4304. http://www.ncbi.nlm.nih.gov/pubmed/1126952.
   PubMed Web of Science ®Google Scholar
• Carpenter, G., and S. Cohen. 1990. “Epidermal Growth Factor.” The Journal of Biological Chemistry 265 (14): 7709–7712. http://www.springerlink.com/index/122465U384255839.pdf.
   PubMed Web of Science ®Google Scholar
• Cohen, S. 1962. “Isolation of a Mouse Submaxillary Gland Protein Accelerating Incisor Eruption and Eyelid Opening in the New-Born Animal.” The Journal of Biological Chemistry 237 (6): 1555–1562. http://www.ncbi.nlm.nih.gov/pubmed/13880319.
   PubMedGoogle Scholar
• Cohen, S. 1965. “The Stimulation of Epidermal Proliferation by a Specific Protein (EGF).” Developmental Biology 12 (3): 394–407. doi:10.1016/0012-1606(65)90005-9.
   PubMed Web of Science ®Google Scholar
• Cohen, S. 1983. “The Epidermal Growth Factor (EGF).” Cancer 51 (10): 1787–1791. doi:10.1002/1097-0142(19830515)51:10<1787::AID-CNCR2820511004>3.0.CO;2-A.
   PubMed Web of Science ®Google Scholar
• Cohen, S., G. Carpenter, and L. King. 1980. “Epidermal Growth Factor-Receptor-Protein Kinase Interactions. Co-Purification of Receptor and Epidermal Growth Factor-Enhanced Phosphorylation Activity.” The Journal of Biological Chemistry 255 (10): 4834–4842.
   PubMed Web of Science ®Google Scholar
• Cohen, S., H. Ushiro, C. Stoscheck, and M. Chinkers. 1982. “A Native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles.” The Journal of Biological Chemistry 257 (3): 1523–1531.
   PubMed Web of Science ®Google Scholar
• Cunningham, D., Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, et al. 2004. “Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer.” New England Journal of Medicine 351 (4): 337–345. doi:10.1056/NEJMoa033025.
   PubMed Web of Science ®Google Scholar
• Cushman, S. M., C. Jiang, A. J. Hatch, I. Shterev, A. B. Sibley, D. Niedzwiecki, A. P. Venook, K. Owzar, H. I. Hurwitz, and A. B. Nixon. 2015. “Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance).” Clinical Cancer Research 21 (5): 1078–1086. doi:10.1158/1078-0432.CCR-14-2313.
   PubMed Web of Science ®Google Scholar
• Derynck, R., A. B. Roberts, M. E. Winkler, E. Y. Chen, and D. V. Goeddel. 1984. “Human Transforming Growth Factor-Alpha: Precursor Structure and Expression in E. Coli.” Cell 38 (1): 287–297. doi:10.1016/0092-8674(84)90550-6.
   PubMed Web of Science ®Google Scholar
• Dong, J., Opresko L. K., Dempsey P. J., Lauffenburger D. A., Coffey R. J., and Wiley H. S. 1999. “Metalloprotease-Mediated Ligand Release Regulates Autocrine Signaling through the Epidermal Growth Factor Receptor.” PNAS 96 (11): 6235–6240. doi:10.1073/pnas.96.11.6235.
   PubMed Web of Science ®Google Scholar
• Douillard, J. Y., S. Siena, J. Cassidy, J. Tabernero, R. Burkes, M. Barugel, Y. Humblet, et al. 2014. “Final Results from PRIME: Randomized Phase III Study of Panitumumab with FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer.” Annals of Oncology 25 (7): 1346–1355. doi:10.1093/annonc/mdu141.
   PubMed Web of Science ®Google Scholar
• Douillard, J. Y., S. Siena, J. Cassidy, J. Tabernero, R. Burkes, M. Barugel, Y. Humblet, et al. 2010. “Randomized, Phase III Trial of Panitumumab with Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) versus FOLFOX4 Alone as First-Line Treatment in Patients with Previously Untreated Metastatic Colorectal Cancer: The PRIME Study.” Journal of Clinical Oncology 28 (31): 4697–4705. doi:10.1200/JCO.2009.27.4860.
   PubMed Web of Science ®Google Scholar
• Duffy, M. J., and J. Crown. 2008. “A Personalized Approach to Cancer Treatment: How Biomarkers Can Help.” Clinical Chemistry 54 54 (11): 1770–1779. doi:10.1373/clinchem.2008.110056.
   PubMed Web of Science ®Google Scholar
• Duffy, M. J., M. Mullooly, N. O'Donovan, S. Sukor, J. Crown, A. Pierce, and P. M. McGowan. 2011. “The ADAMs Family of Proteases: New Biomarkers and Therapeutic Targets for Cancer?” Clinical Proteomics 8 (1): 1–13. doi:10.1186/1559-0275-8-9.
   Google Scholar
• Egner, J. R. 2010. “AJCC Cancer Staging Manual.” JAMA 304 (15): 1726. doi:10.1001/jama.2010.1525.
   Google Scholar
• Falls, D. L., K. M. Rosen, G. Corfas, W. S. Lane, and G. D. Fischbach. 1993. “ARIA, a Protein That Stimulates Acetylcholine Receptor Synthesis, is a Member of the Neu Ligand Family.” Cell 72 (5): 801–813. doi:10.1016/0092-8674(93)90407-H.
   PubMed Web of Science ®Google Scholar
• Galizia, G., E. Lieto, F. De Vita, M. Orditura, P. Castellano, T. Troiani, V. Imperatore, and F. Ciardiello. 2007. “Cetuximab, a Chimeric Human Mouse anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in the Treatment of Human Colorectal Cancer.” Oncogene 26 (25): 3654–3660. doi:10.1038/sj.onc.1210381.
   PubMed Web of Science ®Google Scholar
• Garrett, T. P. J., N. M. McKern, M. Lou, T. C. Elleman, T. E. Adams, G. O. Lovrecz, M. Kofler, et al. 2003. “The Crystal Structure of a Truncated ErbB2 Ectodomain Reveals an Active Conformation, Poised to Interact with Other ErbB Receptors.” Molecular Cell 11 (2): 495–505. doi:10.1016/S1097-2765(03)00048-0.
   PubMed Web of Science ®Google Scholar
• Gee, J. M. W. W., and J. M. Knowlden. 2003. “ADAM Metalloproteases and EGFR Signalling.” Breast Cancer Research 5 (5): 223–224. doi:10.1186/bcr637.
   PubMed Web of Science ®Google Scholar
• Georgopoulos, N. T., L. A. Kirkwood, and J. Southgate. 2014. “A Novel Bidirectional Positive-Feedback Loop between Wnt-β-Catenin and EGFR-ERK Plays a Role in Context-Specific Modulation of Epithelial Tissue Regeneration.” Journal of Cell Science 127 (13): 2967–2982. doi:10.1242/jcs.150888.
   PubMed Web of Science ®Google Scholar
• Goffin, J. R., and K. Zbuk. 2013. “Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline.” Clinical Therapeutics 35 (9): 1282–1303. doi:10.1016/j.clinthera.2013.08.007.
   PubMed Web of Science ®Google Scholar
• Goodearl, A. D., J. B. Davis, K. Mistry, L. Minghetti, M. Otsu, M. D. Waterfield, and P. Stroobant. 1993. “Purification of Multiple Forms of Glial Growth Factor.” The Journal of Biological Chemistry 268 (24): 18095–18102. http://www.ncbi.nlm.nih.gov/pubmed/8394360.
   PubMed Web of Science ®Google Scholar
• Graus-Porta, D., R. R. Beerli, J. M. Daly, and N. E. Hynes. 1997. “ErbB-2, the Preferred Heterodimerization Partner of All ErbB Receptors, is a Mediator of Lateral Signaling.” The EMBO Journal 16 (7): 1647–1655. doi:10.1093/emboj/16.7.1647.
   PubMed Web of Science ®Google Scholar
• Grützmann, R., J. Lüttges, B. Sipos, O. Ammerpohl, F. Dobrowolski, I. Alldinger, S. Kersting, et al. 2004. “ADAM9 Expression in Pancreatic Cancer is Associated with Tumour Type and is a Prognostic Factor in Ductal Adenocarcinoma.” British Journal of Cancer 90 (5): 1053–1058. doi:10.1038/sj.bjc.6601645.
   PubMed Web of Science ®Google Scholar
• Han, C. W., M. S. Jeong, and S. B. Jang. 2017. “Structure, Signaling and the Drug Discovery of the Ras Oncogene Protein.” BMB Reports 50(7): 355–360. doi:10.5483/BMBRep.2017.50.7.062.
   PubMed Web of Science ®Google Scholar
• Han, W., and H.-W. Lo. 2012. “Landscape of EGFR Signaling Network in Human Cancers: Biology and Therapeutic Response in Relation to Receptor Subcellular Locations.” Cancer Letters 318 (2): 124–134. doi:10.1016/j.canlet.2012.01.011.
   PubMed Web of Science ®Google Scholar
• Harty, G., J. Jarrett, and M. Jofre-Bonet. 2018. “Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work.” Applied Health Economics and Health Policy 16 (4): 515–525. doi:10.1007/s40258-018-0395-5.
   PubMed Web of Science ®Google Scholar
• Heinemann, V., D. P. Modest, L. Fischer von Weikersthal, T. Decker, A. Kiani, U. Vehling-Kaiser, S.-E. Al-Batran, et al. 2014. “Gender and Tumor Location as Predictors for Efficacy: Influence on Endpoints in First-Line Treatment with FOLFIRI in Combination with Cetuximab or Bevacizumab in the AIO KRK 0306 (FIRE3) Trial.” Journal of Clinical Oncology 32 (15_suppl): 3600–3600. doi:10.1200/jco.2014.32.15_suppl.3600.
   PubMed Web of Science ®Google Scholar
• Heinemann, V., J. Y. Douillard, M. Ducreux, and M. Peeters. 2013. “Targeted Therapy in Metastatic Colorectal Cancer – An Example of Personalised Medicine in Action.” Cancer Treatment Reviews 39 (6): 592–601. doi:10.1016/j.ctrv.2012.12.011.
   PubMed Web of Science ®Google Scholar
• Higashiyama, S., J. Abraham, J. Miller, J. Fiddes, and M. Klagsbrun. 1991. “A Heparin-Binding Growth Factor Secreted by Macrophage-like Cells That is Related to EGF.” Science 251 (4996): 936–939. doi:10.1126/science.1840698.
   PubMed Web of Science ®Google Scholar
• Higginbotham, J. N., M. Demory Beckler, J. D. Gephart, J. L. Franklin, G. Bogatcheva, G.-J. Kremers, D. W. Piston, et al. 2011. “Amphiregulin Exosomes Increase Cancer Cell Invasion.” Current Biology 21 (9): 779–786. doi:10.1016/j.cub.2011.03.043.
   PubMed Web of Science ®Google Scholar
• Holmes, W. E., M. X. Sliwkowski, R. W. Akita, W. J. Henzel, J. Lee, J. W. Park, D. Yansura, et al. 1992. “Identification of Heregulin, a Specific Activator of P185erbB2.” Science 256 (5060): 1205–1210. doi:10.1126/science.256.5060.1205.
   PubMed Web of Science ®Google Scholar
• Hoque, M. O., S. Begum, M. Brait, C. Jeronimo, M. Zahurak, K. L. Ostrow, E. Rosenbaum, et al. 2008. “Tissue Inhibitor of Metalloproteinases-3 Promoter Methylation is an Independent Prognostic Factor for Bladder Cancer.” Journal of Urology 179 (2): 743–747. doi:10.1016/j.juro.2007.09.019.
   PubMed Web of Science ®Google Scholar
• Horiuchi, K., H. M. Zhou, K. Kelly, K. Manova, and C. P. Blobel. 2005. “Evaluation of the Contributions of ADAMs 9, 12, 15, 17, and 19 to Heart Development and Ectodomain Shedding of Neuregulins Β1 and Β2.” Developmental Biology 283 (2): 459–471. doi:10.1016/j.ydbio.2005.05.004.
   PubMed Web of Science ®Google Scholar
• Hurwitz, H., L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, et al. 2004. “Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer.” New England Journal of Medicine 350 (23): 2335–2342. doi:10.1056/NEJMoa032691.
   PubMed Web of Science ®Google Scholar
• Hutchinson, R. A., R. A. Adams, D. G. McArt, M. Salto-Tellez, B. Jasani, and P. W. Hamilton. 2015. “Epidermal Growth Factor Receptor Immunohistochemistry: New Opportunities in Metastatic Colorectal Cancer.” Journal of Translational Medicine 13 (1): 217. doi:10.1186/s12967-015-0531-z.
   PubMedGoogle Scholar
• Jacobs, B., W. De Roock, H. Piessevaux, R. Van Oirbeek, B. Biesmans, J. De Schutter, S. Fieuws, et al. 2009. “Amphiregulin and Epiregulin MRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated with Cetuximab.” Journal of Clinical Oncology 27 (30): 5068–5074. doi:10.1200/JCO.2008.21.3744.
   PubMed Web of Science ®Google Scholar
• Jing, C., Y. H. Jin, Z. You, Q. Qiong, and Z. Jun. 2016. “Prognostic Value of Amphiregulin and Epiregulin Expression in Metastatic Colorectal Cancer Patients MRNA.” Oncotarget 7 (34): 15–24. doi:10.18632/oncotarget.10151.
   Google Scholar
• Jonker, D. J., C. S. Karapetis, C. Harbison, C. J. O'Callaghan, D. Tu, R. J. Simes, D. P. Malone, et al. 2014. “Epiregulin Gene Expression as a Biomarker of Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer.” British Journal of Cancer 110 (3): 648–655. doi:10.1038/bjc.2013.753.
   PubMed Web of Science ®Google Scholar
• Jonker, D. J., C. J. O'Callaghan, C. S. Karapetis, J. R. Zalcberg, D. Tu, H.-J. Au, S. R. Berry, et al. 2007. “Cetuximab for the Treatment of Colorectal Cancer.” New England Journal of Medicine 357 (20): 2040–2048. doi:10.1056/NEJMoa071834.
   PubMed Web of Science ®Google Scholar
• Karachaliou, N., and R. Rosell. 2018. “Rhomboids and Regulation of Receptor Tyrosine Kinase Ligands Shedding.” Ebiomedicine 37: 19–20. doi:10.1016/j.ebiom.2018.09.053.
   PubMed Web of Science ®Google Scholar
• Karapetis, C. S., S. Khambata-Ford, D. J. Jonker, C. J. O'Callaghan, D. Tu, N. C. Tebbutt, R. J. Simes, et al. 2008. “K-Ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer.” New England Journal of Medicine 359 (17): 1757–1765. doi:10.1056/NEJMoa0804385.
   PubMed Web of Science ®Google Scholar
• Kenny, P. A., and M. J. Bissell. 2007. “Targeting TACE-Dependent EGFR Ligand Shedding in Breast Cancer.” Journal of Clinical Investigation 117 117 (2): 337–345. doi:10.1172/JCI29518.
   PubMed Web of Science ®Google Scholar
• Khambata-Ford, S., C. R. Garrett, N. J. Meropol, M. Basik, C. T. Harbison, S. Wu, T. W. Wong, et al. 2007. “Expression of Epiregulin and Amphiregulin and K-Ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated with Cetuximab.” Journal of Clinical Oncology 25 (22): 3230–3237. doi:10.1200/JCO.2006.10.5437.
   PubMed Web of Science ®Google Scholar
• Kovacs, E., J. A. Zorn, Y. Huang, T. Barros, and J. Kuriyan. 2015. “A Structural Perspective on the Regulation of the Epidermal Growth Factor Receptor.” Annual Review of Biochemistry 84 (1): 739–764. doi:10.1146/annurev-biochem-060614-034402.
   PubMedGoogle Scholar
• Kurohara, K., K. Komatsu, T. Kurisaki, A. Masuda, N. Irie, M. Asano, K. Sudo, et al. 2004. “Essential Roles of Meltrin β (ADAM19) in Heart Development.” Developmental Biology 267 (1): 14–28. doi:10.1016/j.ydbio.2003.10.021.
   PubMed Web of Science ®Google Scholar
• Lacunza, E., R. Canzoneri, M. E. Rabassa, A. Zwenger, A. Segal-Eiras, M. V. Croce, and M. C. Abba. 2012. “RHBDD2: A 5-Fluorouracil Responsive Gene Overexpressed in the Advanced Stages of Colorectal Cancer.” Tumor Biology 33 (6): 2393–2399. doi:10.1007/s13277-012-0503-3.
   PubMedGoogle Scholar
• Lee, J. R., S. Urban, C. F. Garvey, and M. Freeman. 2001. “Regulated Intracellular Ligand Transport and Proteolysis Control EGF Signal Activation in Drosophila.” Cell 107 (2): 161–171. doi:10.1016/S0092-8674(01)00526-8.
   PubMed Web of Science ®Google Scholar
• Lee, M. S., D. G. Menter, and S. Kopetz. 2017. “Right versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes.” Journal of the National Comprehensive Cancer Network 15 (3): 411–419. doi:10.6004/jnccn.2017.0038.
   PubMed Web of Science ®Google Scholar
• Lee, M. S., E. J. McGuffey, J. S. Morris, G. Manyam, V. Baladandayuthapani, W. Wei, V. K. Morris, et al. 2016. “Association of CpG Island Methylator Phenotype and EREG/AREG Methylation and Expression in Colorectal Cancer.” British Journal of Cancer 114 (12): 1352–1361. doi:10.1038/bjc.2016.87.
   PubMed Web of Science ®Google Scholar
• Lemmon, M. A., and J. Schlessinger. 2010. “Cell Signaling by Receptor Tyrosine Kinases.” Cell 141 (7): 1117–1134. doi:10.1016/j.cell.2010.06.011.
   PubMed Web of Science ®Google Scholar
• Lemmon, M. A., J. Schlessinger, and K. M. Ferguson. 2014. “The EGFR Family: Not so Prototypical Receptor Tyrosine Kinases.” Cold Spring Harbor Perspectives in Biology 6 6 (4): a020768. doi:10.1101/cshperspect.a020768.
   PubMed Web of Science ®Google Scholar
• Lendeckel, U., J. Kohl, M. Arndt, S. Carl-McGrath, H. Donat, and C. Röcken. 2005. “Increased Expression of ADAM Family Members in Human Breast Cancer and Breast Cancer Cell Lines.” Journal of Cancer Research and Clinical Oncology 131 (1): 41–48. doi:10.1007/s00432-004-0619-y.
   PubMed Web of Science ®Google Scholar
• Liang, J., S. Balachandra, S. Ngo, and L. E. O’Brien. 2017. “Feedback Regulation of Steady-State Epithelial Turnover and Organ Size.” Nature 548 (7669): 588–591. doi:10.1038/nature23678.
   PubMed Web of Science ®Google Scholar
• Lièvre, A., J. B. Bachet, D. Le Corre, V. Boige, B. Landi, J. F. Emile, J. F. Côté, et al. 2006. “KRAS Mutation Status is Predictive of Response to Cetuximab Therapy in Colorectal Cancer.” Cancer Research 66 (8): 3992–3995. doi:10.1158/0008-5472.CAN-06-0191.
   PubMed Web of Science ®Google Scholar
• Lièvre, A., J.-B. Bachet, V. Boige, A. Cayre, D. Le Corre, E. Buc, M. Ychou, et al. 2008. “KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab.” Journal of Clinical Oncology 26 (3): 374–379. doi:10.1200/JCO.2007.12.5906.
   PubMed Web of Science ®Google Scholar
• Llovet, P., J. Sastre, J. S. Ortega, I. Bando, M. Ferrer, P. García-Alfonso, O. Donnay, et al. 2015. “Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with anti-EGFR Therapy.” Molecular Diagnosis & Therapy 19 (6): 397–408. doi:10.1007/s40291-015-0165-0.
   PubMed Web of Science ®Google Scholar
• Marchionni, M. A., A. D. J. Goodearl, M. Su Chen, O. Bermingham-McDonogh, C. Kirk, M. Hendricks, F. Danehy, et al. 1993. “Glial Growth Factors Are Alternatively Spliced ErbB2 Ligands Expressed in the Nervous System.” Nature 362 (6418): 312–318. doi:10.1038/362312a0.
   PubMed Web of Science ®Google Scholar
• Markman, B., F. J. Ramos, J. Capdevila, and J. Tabernero. 2010. “EGFR and KRAS in Colorectal Cancer.” Advances in Clinical Chemistry 51: 71–119. doi:10.1016/S0065-2423(10)51004-7.
   PubMed Web of Science ®Google Scholar
• Merchant, N. B., I. Voskresensky, C. M. Rogers, B. LaFleur, P. J. Dempsey, R. Graves-Deal, F. Revetta, et al. 2008. “TACE/ADAM-17: A Component of the Epidermal Growth Factor Receptor Axis and a Promising Therapeutic Target in Colorectal Cancer.” Clinical Cancer Research 14 (4): 1182–1191. doi:10.1158/1078-0432.CCR-07-1216.
   PubMed Web of Science ®Google Scholar
• Missiaglia, E., B. Jacobs, G. D'Ario, A. F. Di Narzo, C. Soneson, E. Budinska, V. Popovici, et al. 2014. “Distal and Proximal Colon Cancers Differ in Terms of Molecular, Pathological, and Clinical Features.” Annals of Oncology 25 (10): 1995–2001. doi:10.1093/annonc/mdu275.
   PubMed Web of Science ®Google Scholar
• Mitchell, R. A., R. B. Luwor, and A. W. Burgess. 2018. “Epidermal Growth Factor Receptor: Structure-Function Informing the Design of Anticancer Therapeutics.” Experimental Cell Research 371 (1):1–19. doi:10.1016/j.yexcr.2018.08.009.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. “The Cancer Genome Atlas.” 2018. TCGA. http://cancergenome.nih.gov/abouttcga.
   Google Scholar
• Ohchi, T., Y. Akagi, T. Kinugasa, T. Kakuma, A. Kawahara, T. Sasatomi, Y. Gotanda, et al. 2012. “Amphiregulin is a Prognostic Factor in Colorectal Cancer.” Anticancer Research 32 (6): 2315–2321.
   PubMed Web of Science ®Google Scholar
• Osborne, C. K., B. Hamilton, and M. Nover. 1982. “Receptor Binding and Processing of Epidermal Growth Factor by Human Breast Cancer Cells.” The Journal of Clinical Endocrinology & Metabolism 55 (1): 86–93. doi:10.1210/jcem-55-1-86.
   PubMed Web of Science ®Google Scholar
• Peles, E., S. S. Bacus, R. A. Koski, H. S. Lu, D. Wen, S. G. Ogden, R. B. Levy, and Y. Yarden. 1992. “Isolation of the Neu/HER-2 Stimulatory Ligand: A 44 Kd Glycoprotein That Induces Differentiation of Mammary Tumor Cells.” Cell 69 (1): 205–216. doi:10.1016/0092-8674(92)90131-U.
   PubMed Web of Science ®Google Scholar
• Pentheroudakis, G., V. Kotoula, W. De Roock, G. Kouvatseas, P. Papakostas, T. Makatsoris, D. Papamichael, et al. 2013. “Biomarkers of Benefit from Cetuximab-Based Therapy in Metastatic Colorectal Cancer: Interaction of EGFR Ligand Expression with RAS/RAF, PIK3CA Genotypes.” BMC Cancer 13 (1): 49. doi:10.1186/1471-2407-13-49.
   PubMed Web of Science ®Google Scholar
• Pietrantonio, F., F. Petrelli, A. Coinu, M. Di Bartolomeo, K. Borgonovo, C. Maggi, M. Cabiddu, et al. 2015. “Predictive Role of BRAF Mutations in Patients with Advanced Colorectal Cancer Receiving Cetuximab and Panitumumab: A Meta-Analysis.” European Journal of Cancer 51 (5): 587–594. doi:10.1016/j.ejca.2015.01.054.
   PubMed Web of Science ®Google Scholar
• Prior, I. A, P. D. Lewis, and C. Mattos. 2012. “A Comprehensive Survey of Ras Mutations in Cancer.” Cancer Research 72 (10): 2457–2467. doi:10.1158/0008-5472.CAN-11-2612.
   PubMed Web of Science ®Google Scholar
• Purba, E., E.-I. Saita, and I. Maruyama. 2017. “Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The ‘Rotation Model.” Cells 6 (2): 13. doi:10.3390/cells6020013.
   PubMed Web of Science ®Google Scholar
• Quesnelle, K. M, A. L. Boehm, and J. R. Grandis. 2007. “STAT-Mediated EGFR Signaling in Cancer.” Journal of Cellular Biochemistry 102 (2): 311–319. doi:10.1002/jcb.21475.
   PubMed Web of Science ®Google Scholar
• Quinlan, M., and J. Settleman. 2009. “Isoform-Specific Ras Functions in Development and Cancer.” Future Oncology 5 (1): 105–116. doi:10.2217/14796694.5.1.105.
   PubMed Web of Science ®Google Scholar
• Raghav, K., J. M. Loree, J. S. Morris, M. J. Overman, R. Yu, F. Meric-Bernstam, D. Menter, et al. 2019. “Validation of HER2 Amplification as a Predictive Biomarker for anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer.” JCO Precision Oncology (3): 1–13. doi:10.1200/PO.18.00226.
   Google Scholar
• Richman, S. D., and B. Jasani. 2019. “Predictive Biomarkers and Targeted Therapies in Colorectal Cancer.” In Predictive Biomarkers in Oncology, edited by Badve S., Kumar G., 423–430. Cham: Springer International Publishing. doi:10.1007/978-3-319-95228-4_38.
   Google Scholar
• Richman, S. D., J. Fairley, R. Butler, and Z. C. Deans. 2017. “How Close Are We to Standardised Extended RAS Gene Mutation Testing? The UK NEQAS Evaluation.” Journal of Clinical Pathology 70 (1): 58–62. doi:10.1136/jclinpath-2016-203822.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bigas, M. A., E. H. Lin, and C. H. Crane. 2003. Stage IV Colorectal Cancer. In: Holland-Frei Cancer Medicine, edited by Kufe DW, Pollock RE, Weichselbaum RR, et al., 6th ed. Hamilton (ON): BC Decker. https://www.ncbi.nlm.nih.gov/books/NBK13267/.
   Google Scholar
• Roemer, A., L. Schwettmann, M. Jung, J. Roigas, G. Kristiansen, D. Schnorr, S. A. Loening, K. Jung, and R. Lichtinghagen. 2004. “Increased MRNA Expression of ADAMs in Renal Cell Carcinoma and Their Association with Clinical Outcome.” Oncology Reports 11 (2): 529–536. doi:10.3892/or.11.2.529.
   PubMed Web of Science ®Google Scholar
• Roskoski, R. 2014. “The ErbB/HER Family of Protein-Tyrosine Kinases and Cancer.” Pharmacological Research 79: 34. doi:10.1016/j.phrs.2013.11.002.
   PubMed Web of Science ®Google Scholar
• Sahin, U., G. Weskamp, K. Kelly, H.-M. Zhou, S. Higashiyama, J. Peschon, D. Hartmann, P. Saftig, and C. P. Blobel. 2004. “Distinct Roles for ADAM10 and ADAM17 in Ectodomain Shedding of Six EGFR Ligands.” The Journal of Cell Biology 164 (5): 769–779. doi:10.1083/jcb.200307137.
   PubMed Web of Science ®Google Scholar
• Salvatore, L., G. Aprile, E. Arnoldi, C. Aschele, C. Carnaghi, M. Cosimelli, E. Maiello, et al. 2017. “Management of Metastatic Colorectal Cancer Patients: Guidelines of the Italian Medical Oncology Association (AIOM).” ESMO Open 2 (1): e000147. doi:10.1136/esmoopen-2016-000147.
   PubMed Web of Science ®Google Scholar
• Saridaki, Z., M. Tzardi, C. Papadaki, M. Sfakianaki, F. Pega, A. Kalikaki, E. Tsakalaki, et al. 2011. “Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients.” PLoS One 6 (1): e15980. doi:10.1371/journal.pone.0015980.
   PubMed Web of Science ®Google Scholar
• Savage, C. R., J. H. Hash, and S. Cohen. 1973. “Epidermal Growth Factor. Location of Disulfide Bonds.” The Journal of Biological Chemistry 248 (22): 7669–7672. http://www.ncbi.nlm.nih.gov/pubmed/4750422.
   PubMed Web of Science ®Google Scholar
• Savage, C. R., T. Inagami, and S. Cohen. 1972. “The Primary Structure of Epidermal Growth Factor.” The Journal of Biological Chemistry 247 (23): 7612–7621. http://www.ncbi.nlm.nih.gov/pubmed/4636327.
   PubMed Web of Science ®Google Scholar
• Schneider, M. R, and E. Wolf. 2009. “The Epidermal Growth Factor Receptor Ligands at a Glance.” Journal of Cellular Physiology 218 (3): 460–466. doi:10.1002/jcp.21635.
   PubMed Web of Science ®Google Scholar
• Seals, D. F, and S. A. Courtneidge. 2003. “The ADAMs Family of Metalloproteases: Multidomain Proteins with Multiple Functions.” Genes & Development 17 (1): 7–30. doi:10.1101/gad.1039703.
   PubMed Web of Science ®Google Scholar
• Seligmann, J. F, F. Elliott, S. D. Richman, B. Jacobs, G. Hemmings, S. Brown, J. H. Barrett, S. Tejpar, P. Quirke, and M. T. Seymour. 2016. “Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients with RAS Wild-Type Advanced Colorectal Cancer.” JAMA Oncology 2 (5): 633–642. doi:10.1001/jamaoncol.2015.6065.
   PubMed Web of Science ®Google Scholar
• Seo, M. K., and J. Cairns. 2018. “Do Cancer Biomarkers Make Targeted Therapies Cost-Effective? a Systematic Review in Metastatic Colorectal Cancer.” PLoS One 13 (9): e0204496. doi:10.1371/journal.pone.0204496.
   PubMed Web of Science ®Google Scholar
• Shaib, W., R. Mahajan, and B. El-Rayes. 2013. “Markers of Resistance to anti-EGFR Therapy in Colorectal Cancer.” Journal of Gastrointestinal Oncology 4 (3): 308–318. doi:10.3978/j.issn.2078-6891.2013.029.
   PubMedGoogle Scholar
• Shelly, M., R. Pinkas-Kramarski, B. C. Guarino, H. Waterman, L. M. Wang, L. Lyass, M. Alimandi, et al. 1998. “Epiregulin is a Potent Pan-ErbB Ligand That Preferentially Activates Heterodimeric Receptor Complexes.” Journal of Biological Chemistry 273 (17): 10496–10505. doi:10.1074/jbc.273.17.10496.
   PubMed Web of Science ®Google Scholar
• Shing, Y., G. Christofori, D. Hanahan, Y. Ono, R. Sasada, K. Igarashi, and J. Folkman. 1993. “Betacellulin: A Mitogen from Pancreatic Beta Cell Tumors.” Science 259 (5101): 1604–1607. doi:10.1126/science.8456283.
   PubMed Web of Science ®Google Scholar
• Shoyab, M., G. Plowman, V. McDonald, J. Bradley, and G. Todaro. 1989. “Structure and Function of Human Amphiregulin: A Member of the Epidermal Growth Factor Family.” Science 243 (4894): 1074–1076. doi:10.1126/science.2466334.
   PubMed Web of Science ®Google Scholar
• Sibilia, M., and E. F. Wagner. 1995. “Strain-Dependent Epithelial Defects in Mice Lacking the EGF Receptor.” Science 269 (5221): 234–238. doi:10.1126/science.7618085.
   PubMed Web of Science ®Google Scholar
• Sibilia, M., J. P. Steinbach, L. Stingl, A. Aguzzi, and E. F. Wagner. 1998. “A Strain-Independent Postnatal Neurodegeneration in Mice Lacking the EGF Receptor.” The EMBO Journal 17 (3): 719–731. doi:10.1093/emboj/17.3.719.
   PubMed Web of Science ®Google Scholar
• Sibilia, M., R. Kroismayr, B. M. Lichtenberger, A. Natarajan, M. Hecking, and M. Holcmann. 2007. “The Epidermal Growth Factor Receptor: From Development to Tumorigenesis.” Differentiation 75 (9): 770. doi:10.1111/j.1432-0436.2007.00238.x.
   PubMed Web of Science ®Google Scholar
• Sigismund, S., D. Avanzato, and L. Lanzetti. 2018. “Emerging Functions of the EGFR in Cancer.” Molecular Oncology 12 (1): 3–20. doi:10.1002/1878-0261.12155.
   PubMed Web of Science ®Google Scholar
• Singh, A. B, and R. C. Harris. 2005. “Autocrine, Paracrine and Juxtacrine Signaling by EGFR Ligands.” Cellular Signalling 17 (10): 1183–1193. doi:10.1016/j.cellsig.2005.03.026.
   PubMed Web of Science ®Google Scholar
• Singh, B., G. Carpenter, and R. J. Coffey. 2016. “EGF Receptor Ligands: Recent Advances.” F1000Research 5 (0): 2270. doi:10.12688/f1000research.9025.1.
   Google Scholar
• Sorich, M. J., M. D. Wiese, A. Rowland, G. Kichenadasse, R. A. McKinnon, and C. S. Karapetis. 2015. “Extended RAS Mutations and anti-EGFR Monoclonal Antibody Survival Benefit in Metastatic Colorectal Cancer: A Meta-Analysis of Randomized, Controlled Trials.” Annals of Oncology 26 (1): 13–21. doi:10.1093/annonc/mdu378.
   PubMed Web of Science ®Google Scholar
• Stahler, A., V. Heinemann, C. Giessen-Jung, A. Crispin, A. Schalhorn, S. Stintzing, L. Fischer von Weikersthal, et al. 2016. “Influence of MRNA Expression of Epiregulin and Amphiregulin on Outcome of Patients with Metastatic Colorectal Cancer Treated with 5-FU/LV plus Irinotecan or Irinotecan plus Oxaliplatin as First-Line Treatment (FIRE 1-Trial).” International Journal of Cancer 138 (3): 739–746. doi:10.1002/ijc.29807.
   PubMed Web of Science ®Google Scholar
• Stintzing, S., B. Ivanova, I. Ricard, A. Jung, T. Kirchner, A. Tannapfel, H. Juette, S. Hegewisch-Becker, D. Arnold, and A. Reinacher-Schick. 2018. “Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine plus Bevacizumab Treated MCRC Patients—Analysis of the Phase III AIO KRK-0207 Trial.” Frontiers in Oncology 8: 7796–7807. doi:10.3389/fonc.2018.00474.
   Web of Science ®Google Scholar
• Strachan, L., J. G. Murison, R. L. Prestidge, M. A. Sleeman, J. D. Watson, and K. D. Kumble. 2001. “Cloning and Biological Activity of Epigen, a Novel Member of the Epidermal Growth Factor Superfamily.” Journal of Biological Chemistry 276 (21): 18265–18271. doi:10.1074/jbc.M006935200.
   PubMed Web of Science ®Google Scholar
• Strimpakos, A., G. Pentheroudakis, V. Kotoula, W. De Roock, G. Kouvatseas, P. Papakostas, T. Makatsoris, et al. 2013. “The Prognostic Role of Ephrin A2 and Endothelial Growth Factor Receptor Pathway Mediators in Patients with Advanced Colorectal Cancer Treated with Cetuximab.” Clinical Colorectal Cancer 12 (4): 267–274.e2. doi:10.1016/j.clcc.2013.07.001.
   PubMed Web of Science ®Google Scholar
• Strunk, K. E., V. Amann, and D. W. Threadgill. 2004. “Phenotypic Variation Resulting from a Deficiency of Epidermal Growth Factor Receptor in Mice is Caused by Extensive Genetic Heterogeneity That Can Be Genetically and Molecularly Partitioned.” Genetics 167 (4): 1821–1832. doi:10.1534/genetics.103.020495.
   PubMed Web of Science ®Google Scholar
• Sun, C., and R. Bernards. 2014. “Feedback and Redundancy in Receptor Tyrosine Kinase Signaling: Relevance to Cancer Therapies.” Trends in Biochemical Sciences 39 (10): 465. doi:10.1016/j.tibs.2014.08.010.
   PubMed Web of Science ®Google Scholar
• Tan, C., and X. Du. 2012. “KRAS Mutation Testing in Metastatic Colorectal Cancer.” World Journal of Gastroenterology 18 (37): 5171–5180. doi:10.3748/wjg.v18.i37.5171.
   PubMed Web of Science ®Google Scholar
• Tang, P., P. A. Steck, and W. K. A. Yung. 1997. “The Autocrine Loop of TGF-α/EGFR and Brain Tumors.” Journal of Neuro-Oncology 35 (3): 303–314. doi:10.1023/A:1005824802617.
   PubMed Web of Science ®Google Scholar
• Taylor, J. M., W. M. Mitchell, and S. Cohen. 1972. “Epidermal Growth Factor. Physical and Chemical Properties.” The Journal of Biological Chemistry 247 (18): 5928–5934. http://www.ncbi.nlm.nih.gov/pubmed/5066542.
   PubMed Web of Science ®Google Scholar
• Therkildsen, C., T. K. Bergmann, T. Henrichsen-Schnack, S. Ladelund, and M. Nilbert. 2014. “The Predictive Value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR Treatment in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.” Acta Oncologica 53 (7): 852–864. doi:10.3109/0284186X.2014.895036.
   PubMed Web of Science ®Google Scholar
• Todaro, G. J., C. Fryling, and J. E. De Larco. 1980. “Transforming Growth Factors Produced by Certain Human Tumor Cells: Polypeptides That Interact with Epidermal Growth Factor Receptors.” Proceedings of the National Academy of Sciences 77 (9): 5258–5262. doi:10.1073/pnas.77.9.5258.
   PubMed Web of Science ®Google Scholar
• Tomas, A., C. E. Futter, and E. R. Eden. 2014. “EGF Receptor Trafficking: Consequences for Signaling and Cancer.” Trends in Cell Biology 24 (1): 26. doi:10.1016/j.tcb.2013.11.002.
   PubMed Web of Science ®Google Scholar
• Tomoshige, K., M. Guo, T. Tsuchiya, T. Fukazawa, I. M. Fink-Baldauf, W. D. Stuart, Y. Naomoto, T. Nagayasu, and Y. Maeda. 2018. “An EGFR Ligand Promotes EGFR-Mutant but Not KRAS-Mutant Lung Cancer in Vivo.” Oncogene 37 (28): 3894–3908. doi:10.1038/s41388-018-0240-1.
   PubMed Web of Science ®Google Scholar
• Tougeron, D., T. Lecomte, J. C. Pages, C. Villalva, C. Collin, A. Ferru, J. M. Tourani, C. Silvain, P. Levillain, and L. Karayan-Tapon. 2013. “Effect of Low-Frequency KRAS Mutations on the Response to anti-EGFR Therapy in Metastatic Colorectal Cancer.” Annals of Oncology 24 (5): 1267–1273. doi:10.1093/annonc/mds620.
   PubMed Web of Science ®Google Scholar
• Toyoda, H., T. Komurasaki, D. Uchida, Y. Takayama, T. Isobe, T. Okuyama, and K. Hanada. 1995. “Epiregulin.” Journal of Biological Chemistry 270 (13): 7495–7500. doi:10.1074/jbc.270.13.7495.
   PubMedGoogle Scholar
• Ullrich, A., and J. Schlessinger. 1990. “Signal Transduction by Receptors with Tyrosine Kinase Activity.” Cell 61 (2): 203–212. doi:10.1016/0092-8674(90)90801-K.
   PubMed Web of Science ®Google Scholar
• Vallböhmer, D., and H.-J. Lenz. 2005. “Epidermal Growth Factor Receptor as a Target for Chemotherapy.” Clinical Colorectal Cancer 5: S19–S27. doi:10.3816/CCC.2005.s.003.
   PubMed Web of Science ®Google Scholar
• Van Cutsem, E., and C. H. Köhne. 2009. “Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer.” New England Journal of Medicine 360 (14): 1408–1417. doi:10.1056/NEJMoa0805019.
   PubMed Web of Science ®Google Scholar
• Van Cutsem, E., C.-H. Köhne, I. Láng, G. Folprecht, M. P. Nowacki, S. Cascinu, I. Shchepotin, et al. 2011. “Cetuximab plus Irinotecan, Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival according to Tumor KRAS and BRAF Mutation Status.” Journal of Clinical Oncology 29 (15): 2011–2019. doi:10.1200/JCO.2010.33.5091.
   PubMed Web of Science ®Google Scholar
• Van Cutsem, E., M. Peeters, S. Siena, Y. Humblet, A. Hendlisz, B. Neyns, J.-L. Canon, et al. 2007. “Open-Label Phase III Trial of Panitumumab plus Best Supportive Care Compared with Best Supportive Care Alone in Patients with Chemotherapy-Refractory Metastatic Colorectal Cancer.” Journal of Clinical Oncology 25 (13): 1658–1664. doi:10.1200/JCO.2006.08.1620.
   PubMed Web of Science ®Google Scholar
• Vecchione, L., B. Jacobs, N. Normanno, F. Ciardiello, and S. Tejpar. 2011. “EGFR-Targeted Therapy.” Experimental Cell Research 317 (19): 2765. doi:10.1016/j.yexcr.2011.08.021.
   PubMed Web of Science ®Google Scholar
• Venook, A. P, D. Niedzwiecki, F. Innocenti, B. Fruth, C. Greene, B. H. O'Neil, J. E. Shaw, et al. 2016. “Impact of Primary (1°) Tumor Location on Overall Survival (OS) and Progression-Free Survival (PFS) in Patients (Pts) with Metastatic Colorectal Cancer (MCRC): Analysis of CALGB/SWOG 80405 (Alliance).” Journal of Clinical Oncology 34 (15_suppl): 3504–3504. doi:10.1200/JCO.2016.34.15_suppl.3504.
   Google Scholar
• Venook, A. P, D. Niedzwiecki, H.-J. Lenz, F. Innocenti, M. R. Mahoney, B. H. O’Neil, J. E. Shaw, et al. 2014. “CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (Pts) with KRAS Wild-Type (Wt) Untreated Metastatic Adenocarcinoma of the Colon or Re.” Journal of Clinical Oncology 32 (15_suppl): LBA3–LBA3. doi:10.1200/jco.2014.32.15_suppl.lba3.
   Web of Science ®Google Scholar
• Walker, F., J. Rothacker, C. Henderson, E. C. Nice, B. Catimel, H. H. Zhang, A. M. Scott, et al. 2012. “Ligand Binding Induces a Conformational Change in Epidermal Growth Factor Receptor Dimers.” Growth Factors 30 (6): 394–409. doi:10.3109/08977194.2012.739619.
   PubMed Web of Science ®Google Scholar
• Wang, X., G. Li, S. Koul, R. Ohki, M. Maurer, A. Borczuk, and B. Halmos. 2014. “PHLDA2 is a Key Oncogene-Induced Negative Feedback Inhibitor of EGFR/ErbB2 Signaling via Interference with AKT Signaling.” Oncotarget 9 (38): 24914–24926. doi:10.18632/oncotarget.3674.
   Google Scholar
• Wee, P., and Z. Wang. 2017. “Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways.” Cancers 9 (5). pii: E52. doi:10.3390/cancers9050052.
   Web of Science ®Google Scholar
• Wen, D., E. Peles, R. Cupples, S. V. Suggs, S. S. Bacus, Y. Luo, G. Trail, et al. 1992. “Neu Differentiation Factor: A Transmembrane Glycoprotein Containing an EGF Domain and an Immunoglobulin Homology Unit.” Cell 69 (3): 559–572. doi:10.1016/0092-8674(92)90456-M.
   PubMed Web of Science ®Google Scholar
• Wilson, K. J., C. Mill, S. Lambert, J. Buchman, T. R. Wilson, V. Hernandez-Gordillo, R. M. Gallo, L. M. C. Ades, J. Settleman, and D. J. Riese. 2012. “EGFR Ligands Exhibit Functional Differences in Models of Paracrine and Autocrine Signaling.” Growth Factors 30 (2): 107–116. doi:10.3109/08977194.2011.649918.
   PubMed Web of Science ®Google Scholar
• Yang, X.-D., X. Chi Jia, J. R. F. Corvalan, P. Wang, and C. G. Davis. 2001. “Development of ABX-EGF, a Fully Human anti-EGF Receptor Monoclonal Antibody, for Cancer Therapy.” Critical Reviews in Oncology/Hematology 38 (1): 17–23. doi:10.1016/S1040-8428(00)00134-7.
   PubMed Web of Science ®Google Scholar
• Yang, X.-D., X.-C. Jia, J. R. F. Corvalan, P. Wang, C. G. Davis, and A. Jakobovits. 1999. “Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Hemotherapy Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor W.” Cancer Research 15 (59): 1236–1243.
   Google Scholar
• Yarden, Y. 2001. “The EGFR Family and Its Ligands in Human Cancer. Signalling Mechanisms and Therapeutic Opportunities.” European Journal of Cancer 37 (Suppl 4): 3–8. doi:10.1016/S0959-8049(01)00230-1.
   PubMed Web of Science ®Google Scholar
• Yewale, C., D. Baradia, I. Vhora, S. K. Patil, and A. Misra. 2013. “Epidermal Growth Factor Receptor Targeting in Cancer: A Review of Trends and Strategies.” Biomaterials 34 (34): 8690–8707. doi:10.1016/j.biomaterials.2013.07.100.
   PubMed Web of Science ®Google Scholar
• Zhang, L., Y. Zhao, Y. Dai, J.-N. Cheng, Z. Gong, Y. Feng, C. Sun, Q. Jia, and B. Zhu. 2018. “Immune Landscape of Colorectal Cancer Tumor Microenvironment from Different Primary Tumor Location.” Frontiers in Immunology 9 (9): 1578. doi:10.3389/fimmu.2018.01578.
   PubMedGoogle Scholar
• Zhou, B.-B. S., J. S. Fridman, X. Liu, S. M. Friedman, R. C. Newton, and P. A. Scherle. 2005. “ADAM Proteases, ErbB Pathways and Cancer.” Expert Opinion on Investigational Drugs 14 (6): 591–606. doi:10.1517/13543784.14.6.591.
   PubMed Web of Science ®Google Scholar